{"id":497546,"date":"2024-01-26T19:30:51","date_gmt":"2024-01-27T00:30:51","guid":{"rendered":"https:\/\/platohealth.ai\/genentechs-i-shaped-abs-a-bispecific-dendritic-t-cell-engager-and-more\/"},"modified":"2024-01-27T07:15:44","modified_gmt":"2024-01-27T12:15:44","slug":"genentechs-i-shaped-abs-a-bispecific-dendritic-t-cell-engager-and-more","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/genentechs-i-shaped-abs-a-bispecific-dendritic-t-cell-engager-and-more\/","title":{"rendered":"Genentech\u2019s i-shaped Abs; a bispecific dendritic-T cell engager and more","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"

ARTICLE | Discovery & Translation<\/p>\n

\n
\n
\n

BioCentury\u2019s roundup of translational innovations<\/h2>\n

\n By Danielle Golovin, Senior Biopharma Analyst<\/span>\n<\/p>\n

January 27, 2024 12:30 AM UTC<\/p>\n<\/div>\n<\/div>\n<\/div>\n

<\/span><\/span><\/div>\n

The Genentech Inc. unit of  Roche<\/a> (SIX:ROG; OTCQX:RHHBY) reported<\/a> in Nature Communications<\/i> i-shaped antibody agonists that more closely recapitulate the biology of natural ligands than traditional Y-shaped antibodies. By adjusting the geometry by which the IgG Fab arms engage target receptors, the scientists were able to create monospecific i-shaped antibody agonists of several tumor necrosis factor receptor superfamily members and bispecific agonists of IL-2RB and IL-2RG.<\/p>\n

Researchers from  Weizmann Institute of Science<\/a> and Tel Aviv University<\/a> published<\/a> in Cell<\/i> a bispecific DC-T cell engager (BiCE) that facilitates interaction between PD-1+<\/sup> T cells and CLEC9A+<\/sup> conventional type I dendritic cells. The BiCE enhanced tumor-specific T cell proliferation and remodeled tumor-infiltrating lymphocyte states and frequencies to favor tumor elimination in mouse models of cancer, including ones resistant to traditional anti-PD-1 therapy…<\/p>\n